MWMark David Wilkie

Mark David Wilkie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark David Wilkie has a total of 128 co-authors. Here are the top co-authors by number of shared publications:

  • Jeffrey Lancaster

    Liverpool Head and Neck Centre, Department of Otolaryngology/Head and Neck Surgery Aintree University Hospital Liverpool UK

    6 shared publications
  • Terence M. Jones

    Liverpool Head and Neck Centre, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, United Kingdom

    5 shared publications
  • Benjamin Hall

    3 shared publications
  • Kathryn A. Lightbody

    Department of Otorhinolaryngology – Head and Neck Surgery University Hospital Aintree Liverpool United Kingdom

    3 shared publications
  • Nicholas J. Roland

    Liverpool Head and Neck Centre, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, United Kingdom

    3 shared publications
  • Nikolina Vlatković

    MCP Hahnemann University Cancer Center, Philadelphia, PA 19102, USA

    3 shared publications

Latest Publications

  • Open Access

    Enhanced Recovery After Surgery Protocol in Transoral Robotic Surgery: A Case–Control Study

    by Jonathan Daniel, Raguwinder Bindy Sahota, Mark David Wilkie, Lee Pryor, Ahmed Bassiouni, Jake Jervis‐Bardy, Arun Takhar, Bora Jeong, Oladejo Olaleye, Suren Krishnan, et al.

    Introduction: ‘Enhanced Recovery After Surgery’ (ERAS) protocols have been developed for multiple surgical procedures with favourable outcome measures including Length of Stay (LoS). Trans‐Oral Robotic Surgery (TORS) has similarly facilitated earlier patient discharges, particularly in comparison to open head and neck surgical techniques. There is a dearth of literature on the effect of ERAS protocols in TORS. We sought to comprehensively examine the effect of a TORS ERAS protocol across several key metrics, with a focus on LoS. Methods: We conducted a retrospective cohort study following implementation of a TORS ERAS protocol. This protocol was developed at our institution and implemented in 2021; it included key features such as pharyngocutaneous risk stratification and thorough perioperative assessments. Patients managed prior to (p‐ERAS) and post implementation (w‐ERAS) were separated into two groups, with key outcomes, including LoS, estimated cost per patient, return to swallow, and complication rate, compared. Results: A total of 40 TORS cases were included. Patients managed w‐ERAS had a mean adherence rate to protocol of 90%. The w‐ERAS group showed a statistically significant reduction in median length of stay by 3.5 days ( p = 0.03) when compared to the p‐ERAS group. There was also a trend towards decreased median cost per patient as well as decreased median time to oral intake. Conclusion: Our study demonstrates an easily implementable protocol for the perioperative management of TORS oncological surgery. The use of this ERAS protocol demonstrated a significant reduction in patient length of stay in a small sample size.

  • Head and Neck Squamous Cell Carcinoma of Unknown Primary—Who Can Be Offered Surgery as the Sole Treatment Modality? A Systematic Review

    by Arunjit Takhar, Mark D. Wilkie, Devraj Srinivasan, Emma King

    Objective: Evaluate the role of surgery as the sole treatment modality for patients with cervical head and neck squamous cell carcinoma of unknown primary (HNSCCUP).Design: Systematic review of observational cohort studies with qualitative synthesis.Setting: PubMed, Ovid EMBASE, and Cochrane Controlled register of Trials (CENTRAL) were screened from January 2000 up to October 2021.Participants: Patients with HNSCCUP after completing diagnostic workup subsequently treated with single‐modality surgery.Main Outcome Measures: The primary outcome was 3‐year overall survival (OS). Secondary outcomes included disease‐free survival (DFS), primary emergence, regional recurrence, and distant metastasis.Results: Fourteen eligible studies were identified, including 1780 patients, of whom 294 received surgery as their sole treatment (seven studies) with 3‐year OS ranging from 43.9% to 100%. 3‐year DFS was reported in four studies (n = 62) ranging from 42.8% to 67.0%. 5‐year OS and DFS were available in three studies (n = 31), ranging from 36.6% to 75.0%, and 43.6% to 67.0%, respectively. The rate of primary emergence ranged from 11.1% to 33.3% (seven studies, n = 157), regional relapse from 0.0% to 50.0% (five studies, n = 60) and distant metastasis from 0.0% to 3.3% (three studies, n = 45). Patients undergoing surgery as a sole treatment had predominantly p16/HPV positive N1 (TNM7) disease without ECS.Conclusion: Outcomes for HNSCCUP patients undergoing surgery alone range widely in the literature but may be reasonable in a subset of patients with early‐stage p16/HPV positive disease. Data is lacking for p16/HPV negative disease where the potential primary site is more varied and primary emergence appears more common.


  • Open Access

    Head and neck squamous cell carcinoma of unknown primary - Who can be offered surgery as the sole treatment modality? A systematic review

    by Arunjit Takhar, Mark Wilkie, Devraj Srinivasan, Emma King

    Objective Evaluate the role of neck dissection (ND) as the sole treatment modality for patients with cervical head and neck squamous cell carcinoma of unknown primary (HNSCCUP). Design Systematic review of observational cohort studies with qualitative synthesis. Setting PubMed, Ovid EMBASE, and Cochrane Controlled register of Trials (CENTRAL) were screened from January 2000 up to October 2021. Participants HNSCCUP patients undergoing ND. Main Outcome Measures The primary outcome was 3-year overall survival (OS). Secondary outcomes included disease-free survival (DFS), primary emergence, regional recurrence, and distant metastasis. Results Fourteen eligible studies were identified, including 1,780 patients, of whom 294 received ND as their sole treatment (seven studies) with 3-year OS ranging from 43.9% to 100%. 3-year DFS was reported in four studies (n=62) ranging from 42.8% to 67.0%. 5-year OS and DFS were available in three studies (n=31), ranging from 36.6% to 75.0%, and 43.6% to 67.0%, respectively. The rate of primary emergence ranged from 11.1% to 33.3% (seven studies, n=157), regional relapse from 0.0% to 50.0% (five studies, n=60), and distant metastasis from 0.0% to 3.3% (three studies, n=45). Patients undergoing ND as a sole treatment had predominantly p16 positive N1 (TNM7) disease without ECS. Conclusion Outcomes for HNSCCUP patients undergoing ND alone range widely in the literature but appear reasonable in a subset of patients with early stage p16 positive disease. Data is lacking for p16 negative disease where the potential primary site is more varied and primary emergence appears more common.

  • Predictors of non‐functional larynx following (chemo)radiotherapy for locally advanced laryngeal cancer

    by Kristijonas Milinis, Rhydian King, Jeffrey Lancaster, Rachel Brooker, Rebecca Zammitt, Mark D. Wilkie, Jason C. Fleming, Katharine Davies


  • Open Access

    Predictors of non-functional larynx following (chemo)radiotherapy for locally advanced laryngeal cancer

    by Kristijonas Milinis, Rhydian King, Rachel Brooker, Rebecca Zammitt, Mark Wilkie, Jason Fleming, Katharine Davies

    • Non-functional larynx (NFL) was found to affect 30.9 % of patients with locally advanced laryngeal cancer who underwent curative non-surgical laryngeal preservation treatment for stage III/IV disease • The key measures of NFL were long-term gastrostomy and tracheostomy dependence, functional laryngectomy and chronic aspiration. • Multivariate analyses identified current smoking to be associated with 6.8-fold increase in NFL • Patients with pre-treatment hemi-laryngeal fixation were 3.4 times more likely to experience locoregional recurrence.

  • Open Access

    Metabolic Plasticity and Combinatorial Radiosensitisation Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck Cell Lines

    by Mark D. Wilkie, Emad A. Anaam, Andrew S. Lau, Carlos P. Rubbi, Nikolina Vlatkovic, Terence M. Jones, Mark T. Boyd

    Background: A major objective in the management of human papillomavirus (HPV)-positive squamous cell carcinoma of the head and neck (SCCHN) is to reduce long-term functional ramifications while maintaining oncological outcomes. This study examined the metabolic profile of HPV-positive SCCHN and the potential role of anti-metabolic therapeutics to achieve radiosensitisation as a potential means to de-escalate radiation therapy. Methods: Three established HPV-positive SCCHN cell lines were studied (UM-SCC-104, UPCI:SCC154, and VU-SCC-147), together with a typical TP53 mutant HPV-negative SCCHN cell line (UM-SCC-81B) for comparison. Metabolic profiling was performed using extracellular flux analysis during specifically designed mitochondrial and glycolytic stress tests. Sensitivity to ionising radiation (IR) was evaluated using clonogenic assays following no treatment, or treatment with: 25 mM 2-deoxy-D-glucose (glycolytic inhibitor) alone; 20 mM metformin (electron transport chain inhibitor) alone; or 25 mM 2-deoxy-D-glucose and 20 mM metformin combined. Expression levels of p53 and reporters of p53 function (MDM2, p53, Phospho-p53 [Ser15], TIGAR and p21 [CDKN1A]) were examined by western blotting. Results: HPV-positive SCCHN cell lines exhibited a diverse metabolic phenotype, displaying robust mitochondrial and glycolytic reserve capacities. This metabolic profile, in turn, correlated with IR response following administration of anti-metabolic agents, in that both 2-deoxy-D-glucose and metformin were required to significantly potentiate the effects of IR in these cell lines. Conclusions: In contrast to our recently published data on HPV-negative SCCHN cells, which display relative glycolytic dependence, HPV-positive SCCHN cells can only be sensitised to IR using a complex anti-metabolic approach targeting both mitochondrial respiration and glycolysis, reflecting their metabolically diverse phenotype. Notionally, this may provide an attractive platform for treatment de-intensification in the clinical setting by facilitating IR dose reduction to minimise the impact of treatment on long-term function.


  • P-226 Emergency presentations of head and neck cancer: our experience in the wake of the COVID-19 pandemic

    by Mark D. Wilkie, Peter Gaskell, Benjamin Hall, Terence M. Jones, Andrew J. Kinshuck

  • Open Access

    Emergency presentations of head and neck cancer: Our experience in the wake of the COVID‐19 pandemic

    by Mark D. Wilkie, Peter Gaskell, Benjamin Hall, Terence M. Jones, Andrew J. Kinshuck

    Click on the article title to read more.


  • Open Access

    EMERGENCY PRESENTATIONS OF HEAD AND NECK CANCER: OUR EXPERIENCE IN THE WAKE OF THE COVID-19 PANDEMIC

    by Mark Wilkie, Peter Gaskell, Benjamin Hall, Terry Jones, Andrew Kinshuck

    A document by Mark Wilkie, written on Authorea.